Lebrikizumab is an investigational monoclonal antibody that binds to the IL-13 protein with high affinity and inhibits its signaling.
Almirall SA (BME:ALM) announces that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the marketing authorization of EBGLYSS® (lebrikizumab) for the treatment of adults and adolescents (at least 12 years of age and… . + Read more
The application to the EMA is based on results from the phase III studies ADvocate 1, 2 and ADhere. + read more
In Spain, more than 2 million people currently suffer from this condition. + read more
67% of adolescent patients have difficulty falling asleep, which is crucial for growth and development. + read more
LEO Pharma Announces European Commission Approval of Adtralza® (tralokinumab) is used to treat moderate to severe atopic dermatitis in adolescents. + read more
In monotherapy or combination therapy, it can relieve symptoms and improve patients’ quality of life. + read more
Four out of 10 Madrid residents do not believe that atopic dermatitis affects sleep, self-esteem or stress. + read more
Publishers Mindscape Developers P.F. Magic Release date 1998 Genre Simulation Game rating Description of the…
Editors Activision, Inc. Developers superego games Release date 2006 Gender Adventure Game Rating Game Description…
Editors Terraglyph Interactive Studios, Warner Bros. Interactive Entertainment. Developers Terraglifo interactive studios Release date nineteen…
Editors Sega, Digital Images, Screaming Villains, Limited Run Games Developers Digital Images, Inc. Release date…
Editors Davilex Games BV Developers Davilex Games BV Release date 1998 Gender Careers Game Rating…
Editors Sony Computer Entertainment, Disney Interactive Studios Developers High voltage software Release date 2002 Gender…